motilis

Motilis is a brand name for a medication used to treat irritable bowel syndrome (IBS) with constipation. It is a proprietary formulation of the drug linaclotide, which belongs to a class of drugs known as guanylate cyclase-C (GC-C) agonists. Linaclotide works by stimulating the production of nitric oxide in the gut, which helps to relax the muscles in the intestines and increase the movement of stool through the digestive system.

Motilis is available in the form of a liquid suspension for oral administration. It is typically taken once daily, with or without food. The medication is not intended for use in patients with severe constipation or bowel obstruction.

The most common side effects of motilis include abdominal pain, diarrhea, and nausea. These side effects are usually mild and temporary. Serious side effects are rare but can include severe abdominal pain, blood in the stool, and allergic reactions.

Motilis was approved by the U.S. Food and Drug Administration (FDA) in 2010 and by the European Medicines Agency (EMA) in 2011. It is marketed by Takeda Pharmaceuticals. The medication is available by prescription only and should be used under the guidance of a healthcare professional.